SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Shuttle Pharmaceuticals Holdings

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 9.99% in Shuttle Pharmaceuticals Holdings, Inc.'s common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Shuttle Pharmaceuticals Holdings, Inc.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 444,635 shares of common stock of Shuttle Pharmaceuticals Holdings, Inc.
• This ownership represents 9.99% of the issuer's common stock.
• Armistice Capital, LLC, as the investment manager, and Steven Boyd, as its managing member, share voting and dispositive power over these shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive investment by a reputable capital firm, which can be seen as a positive signal of confidence in the company. There are no negative disclosures.

Positives

• A significant institutional investor, Armistice Capital, and its managing member, Steven Boyd, hold a substantial 9.99% stake, indicating confidence in the company.
• The filing confirms the shares are held for investment purposes in the ordinary course of business, not for control-related intentions.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an investment firm in a publicly traded company. It does not provide specific industry context beyond identifying the issuer as Shuttle Pharmaceuticals Holdings, Inc., which is likely in the pharmaceutical sector given its name.

Stakeholder Impact

• Shareholders may view the significant stake held by Armistice Capital and Steven Boyd as a positive indicator of institutional confidence in Shuttle Pharmaceuticals Holdings, Inc.

Key Dates

Keywords

Shuttle Pharmaceuticals Holdings Inc., Armistice Capital LLC, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake